(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 July 2011 (14.07.2011)

PCT

(10) International Publication Number
WO 2011/085361 A1

(51) International Patent Classification:
A61K 31/7076 (2006.01) *A61P 27/02* (2006.01)
A61K 31/5575 (2006.01)

(21) International Application Number:
PCT/US2011/020808

(22) International Filing Date:
11 January 2011 (11.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/293,806 11 January 2010 (11.01.2010) US

(71) Applicant *(for all designated States except US)*: **INOTEK PHARMACEUTICALS CORPORATION** [US/US]; 33 Hayden Avenue, Second Floor, Lexington, MA 02421 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIM, Norman, N.** [US/US]; 2 Honeysuckle Road, Westford, MA 01886 (US). **MCVICAR, William, K.** [US/US]; 31 Powers Road, Sudbury, MA 01776 (US). **MCCAULEY, Thomas** [US/US]; 85 Gore Street, Cambridge, MA 02141 (US). **BAUMGARTNER, Rudolf, A.** [US/US]; 22 Munnings Drive, Sudbury, MA 01776-1221 (US).

(74) Agents: **REMILLARD, Jane E.** et al.; Nelson Mullins Riley & Scarborough LLP, One Post Offfice Square, Boston, MA 02109-2127 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE

Figure 5
Mean IOP Measured Over Several Days Following Repeated Ocular Administration of Latanoprost Alone or in Combination with Compound A in Normotensive Monkeys



(57) **Abstract**: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan ™ and Compound A.

WO 2011/085361 A1